Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN S KHOURY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1255549713
CMS profile
238160
Location
ABINGTON, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$121,156.35

176 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN S KHOURY

NPI 1255549713 · CMS profile ID 238160

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ABINGTON, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255549713?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN S KHOURY, NPI 1255549713, CMS profile ID 238160. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255549713?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOHN S KHOURY, NPI 1255549713, CMS profile ID 238160. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255549713?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOHN S KHOURY, NPI 1255549713, CMS profile ID 238160, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1255549713?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

176 matching records · $121,156.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 176 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 176.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $430.8010/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603573 CMS
JAZZ PHARMACEUTICALS INC. $3,080.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608659 CMS
JAZZ PHARMACEUTICALS INC. $258.8010/08/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603305 CMS
JAZZ PHARMACEUTICALS INC. $3,960.0010/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603129 CMS
JAZZ PHARMACEUTICALS INC. $3,080.0010/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608715 CMS
JAZZ PHARMACEUTICALS INC. $3,080.0010/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608359 CMS
JAZZ PHARMACEUTICALS INC. $130.5010/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603125 CMS
JAZZ PHARMACEUTICALS INC. $137.2510/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603127 CMS
JAZZ PHARMACEUTICALS INC. $130.5010/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603121 CMS
JAZZ PHARMACEUTICALS INC. $136.5010/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603123 CMS
JAZZ PHARMACEUTICALS INC. $766.1310/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608657 CMS
JAZZ PHARMACEUTICALS INC. $1,167.1310/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608713 CMS
JAZZ PHARMACEUTICALS INC. $119.8010/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608709 CMS
Biogen, Inc. $23.0009/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827840811 CMS
JAZZ PHARMACEUTICALS INC. $120.2909/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608651 CMS
HARMONY BIOSCIENCES LLC $31.6009/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853075311 CMS
JAZZ PHARMACEUTICALS INC. $112.9609/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603135 CMS
Alexion Pharmaceuticals, Inc. $21.2209/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783116449 CMS
JAZZ PHARMACEUTICALS INC. $1,140.1909/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608357 CMS
JAZZ PHARMACEUTICALS INC. $118.3009/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608355 CMS
JAZZ PHARMACEUTICALS INC. $626.8009/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603119 CMS
JAZZ PHARMACEUTICALS INC. $680.0009/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604817 CMS
JAZZ PHARMACEUTICALS INC. $24.3409/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845559693 CMS
JAZZ PHARMACEUTICALS INC. $299.2509/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608719 CMS
UCB, Inc. $18.2509/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807421911 CMS
JAZZ PHARMACEUTICALS INC. $3,080.0009/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603157 CMS
HARMONY BIOSCIENCES LLC $28.3908/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853075307 CMS
JAZZ PHARMACEUTICALS INC. $23.3408/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845557095 CMS
JAZZ PHARMACEUTICALS INC. $859.8808/26/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603155 CMS
JAZZ PHARMACEUTICALS INC. $94.9608/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603161 CMS
JAZZ PHARMACEUTICALS INC. $178.4008/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608277 CMS
JAZZ PHARMACEUTICALS INC. $117.3208/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608279 CMS
JAZZ PHARMACEUTICALS INC. $3,080.0008/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608379 CMS
JAZZ PHARMACEUTICALS INC. $1,100.0008/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608919 CMS
JAZZ PHARMACEUTICALS INC. $122.0608/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608369 CMS
JAZZ PHARMACEUTICALS INC. $1,225.0608/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608377 CMS
Biohaven Pharmaceuticals, Inc. $15.9008/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852536725 CMS
Merck Sharp & Dohme Corporation $11.7708/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848380925 CMS
Amgen Inc. $20.2608/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825442439 CMS
JAZZ PHARMACEUTICALS INC. $3,080.0008/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608349 CMS
Kyowa Kirin, Inc. $16.2607/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852987403 CMS
JAZZ PHARMACEUTICALS INC. $3,080.0007/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608123 CMS
HARMONY BIOSCIENCES LLC $25.8907/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853075309 CMS
JAZZ PHARMACEUTICALS INC. $3,960.0007/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607903 CMS
JAZZ PHARMACEUTICALS INC. $105.3007/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608347 CMS
JAZZ PHARMACEUTICALS INC. $3,960.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845606859 CMS
JAZZ PHARMACEUTICALS INC. $235.0307/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607899 CMS
JAZZ PHARMACEUTICALS INC. $583.6207/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607901 CMS
JAZZ PHARMACEUTICALS INC. $2,000.0007/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608417 CMS
JAZZ PHARMACEUTICALS INC. $183.6507/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607759 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $94,771.84 198
PY2020 $60,391.43 108
PY2021 $121,156.35 176
PY2022 $92,117.35 203
PY2023 $120,234.31 223
PY2024 $100,405.30 196
PY2025 $96,647.24 200

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $222,368.54 103
PY2024 Principal investigator $368,745.24 248
PY2023 Principal investigator $63,220.28 31
PY2021 Principal investigator $10.88 1
PY2020 Principal investigator $12,988.07 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

103 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736772
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $45.61 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736774
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8.12 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736776
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $118.70 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736782
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $66.00 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736784
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.66 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736786
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.75 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736790
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11.00 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736792
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.00 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736794
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736796
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.33 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736798
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.20 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736800
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $28.05 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736802
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $119.28 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736804
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.68 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736806
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.64 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736808
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.92 11/24/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736810
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,926.00 10/13/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736778
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12,327.00 10/13/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736780
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 10/13/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736788
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 10/13/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736812
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,056.40 09/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736748
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 09/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736752
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,926.00 09/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736758
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,500.00 09/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736760
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16,191.00 09/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736762
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12,327.00 09/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736770
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $39,050.58 08/21/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736750
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16,191.00 08/21/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736756
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,056.00 08/21/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736764
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,500.00 08/21/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736766
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,500.00 08/20/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736768
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $360.00 08/06/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736754
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,793.05 07/11/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736746
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613195
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613209
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613996
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614006
Principal investigator 1 Alkermes, Inc. $33.32 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615301
Principal investigator 1 Alkermes, Inc. $4.90 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615763
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616437
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617215
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617477
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617887
Principal investigator 1 Alkermes, Inc. $72.80 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618365
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618777
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618873
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618997
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619581
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619595
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619607
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619809
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620067
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620431
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620445
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620520
Principal investigator 1 Alkermes, Inc. $5.88 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620664
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621156
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621266
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621556
Principal investigator 1 Alkermes, Inc. $5.95 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621746
Principal investigator 1 Alkermes, Inc. $54.60 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622611
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623080
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623088
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623982
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624016
Principal investigator 1 Alkermes, Inc. $1.05 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625095
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626860
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.05 06/11/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736738
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736740
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 06/11/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736742
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.07 06/11/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736744
Principal investigator 1 Alkermes, Inc. $10,000.00 05/16/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614537
Principal investigator 1 Alkermes, Inc. $895.83 05/16/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617197
Principal investigator 1 Alkermes, Inc. $2,032.00 05/16/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623796
Principal investigator 1 Alkermes, Inc. $650.00 05/16/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624040
Principal investigator 1 Alkermes, Inc. $77.64 04/03/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613627
Principal investigator 1 Alkermes, Inc. $119.36 04/03/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613631
Principal investigator 1 Alkermes, Inc. $113.34 04/03/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615993
Principal investigator 1 Alkermes, Inc. $82.08 04/03/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623372
Principal investigator 1 Alkermes, Inc. $52.48 04/03/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624018
Principal investigator 1 Alkermes, Inc. $56.85 04/03/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624024
Principal investigator 1 Alkermes, Inc. $259.54 04/03/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626004
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,791.49 03/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736712
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $21.78 03/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736716
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,727.57 03/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736734
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,211.08 02/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736704
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,791.49 02/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736706
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,024.76 02/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736710
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,211.08 02/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736720
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,415.21 02/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736728
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,024.76 02/03/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736736
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736708
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736714
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736718
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736730
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,440.67 01/17/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736702
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,065.50 01/17/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736722
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,727.57 01/17/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736724
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,727.57 01/17/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736726
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,415.21 01/17/2025 Non-covered Recipient Entity
Abington Neurological Associates, LTD
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736732
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627156
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES, LTD.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627228